这笔资金将用于建立Myricx的专有抗体偶联药物(ADC)载荷平台,该平台以N-肉豆蔻酰转移酶抑制剂(NMTi)为有效载荷。该资金并用以推进其NMTi-ADC管线,通过靶向经临床验证的肿瘤相关抗原以完成临床概念验证。
NMT是一种可以向几种关键的癌细胞生存蛋白靶点添加特定的脂质修饰的酶。Myricx正在推进基于其NMT抑制剂载荷化学平台的ADC管线,以解决肿瘤学中严重未满足的需求,并已在多个实体瘤相关抗原和癌细胞类型中观察到积极的临床前疗效和安全性。 过往的数据显示,Myricx的初代NMTi-ADC在多个实体瘤模型中,以良好耐受的剂量实现了完全且持久的肿瘤消退,这些肿瘤对带有Topo1抑制剂的ADC耐药。此外,这些NMTi-ADC表现出强大的旁观者效应,并在广泛的抗原表达水平下,在人源肿瘤异种移植(PDX)类器官模型中展示了强劲疗效。
参考资料:
[1] Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development. Retrieved July 8, 2024 from https://myricxbio.com/myricx-bio-announces-90m-114m-series-a-financing-to-advance-its-novel-nmti-adc-therapeutics-into-clinical-development/
<br>